Dataset Information
Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology.
Ontology highlight
ABSTRACT: Aims
Knowledge of consumer perspectives of personalized medicine (PM) is limited. Our study assessed consumer perspectives of PM, with a focus on oncology care, to inform industry, clinician and payer stakeholders' programs and policy.Materials & methods
A nationally representative survey of 602 US consumers' ≥30 years old explored familiarity, perspectives and expected value of PM.Results
Most (73%) respondents have not heard of 'personalized medicine,' though after understanding the term most (95%) expect PM to have a positive beneft. Consumer's willingness to pay is associated with products' impact on survival, rather than predicting disease risk. If testing indicates consumers are not candidates for oncology therapies, most (84%) would seek a second opinion or want therapy anyway.Conclusions
Understanding heterogeneity in consumer perspectives of PM can inform program and policy development.
SUBMITTER: Garfeld S
PROVIDER: S-EPMC4303575 | biostudies-literature | 2015 Jan
REPOSITORIES: biostudies-literature
Publications
Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology.
Personalized medicine 20150101 1
<h4>Aims</h4>Knowledge of consumer perspectives of personalized medicine (PM) is limited. Our study assessed consumer perspectives of PM, with a focus on oncology care, to inform industry, clinician and payer stakeholders' programs and policy.<h4>Materials & methods</h4>A nationally representative survey of 602 US consumers' ≥30 years old explored familiarity, perspectives and expected value of PM.<h4>Results</h4>Most (73%) respondents have not heard of 'personalized medicine,' though after unde ...[more]